End-of-day quote
Shanghai S.E.
06:00:00 2024-07-14 pm EDT
|
5-day change
|
1st Jan Change
|
29.85
CNY
|
-3.93%
|
|
-0.83%
|
-45.54%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
28,321
|
28,531
|
22,628
|
12,348
|
-
|
-
|
Enterprise Value (EV)
1 |
28,321
|
28,531
|
22,628
|
12,348
|
12,348
|
12,348
|
P/E ratio
|
111
x
|
157
x
|
45.3
x
|
17.4
x
|
13.2
x
|
11
x
|
Yield
|
-
|
0.22%
|
0.27%
|
1.03%
|
1.35%
|
1.93%
|
Capitalization / Revenue
|
23.6
x
|
26.6
x
|
12.4
x
|
4.99
x
|
4.08
x
|
3.54
x
|
EV / Revenue
|
23.6
x
|
26.6
x
|
12.4
x
|
4.99
x
|
4.08
x
|
3.54
x
|
EV / EBITDA
|
85.5
x
|
108
x
|
34.7
x
|
13.3
x
|
11.1
x
|
9.57
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
8.29
x
|
8.02
x
|
5.63
x
|
2.62
x
|
2.23
x
|
1.89
x
|
Nbr of stocks (in thousands)
|
412,841
|
412,841
|
412,841
|
413,658
|
-
|
-
|
Reference price
2 |
68.60
|
69.11
|
54.81
|
29.85
|
29.85
|
29.85
|
Announcement Date
|
2/18/22
|
2/24/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
1,202
|
1,071
|
1,825
|
2,474
|
3,024
|
3,491
|
EBITDA
1 |
-
|
331.2
|
263.5
|
651.3
|
926.9
|
1,116
|
1,291
|
EBIT
1 |
-
|
261.9
|
187
|
559.3
|
807.6
|
1,058
|
1,271
|
Operating Margin
|
-
|
21.79%
|
17.46%
|
30.65%
|
32.64%
|
34.99%
|
36.42%
|
Earnings before Tax (EBT)
1 |
-
|
261.6
|
197.8
|
563.8
|
804.2
|
1,063
|
1,277
|
Net income
1 |
418.2
|
243.6
|
181.6
|
501
|
710.5
|
931.3
|
1,120
|
Net margin
|
-
|
20.26%
|
16.95%
|
27.46%
|
28.72%
|
30.79%
|
32.07%
|
EPS
2 |
1.140
|
0.6200
|
0.4400
|
1.210
|
1.712
|
2.256
|
2.712
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
0.1500
|
0.1500
|
0.3080
|
0.4030
|
0.5750
|
Announcement Date
|
4/2/21
|
2/18/22
|
2/24/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
507
|
911
|
775
|
303
|
642
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
60.57
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
0.1500
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/19/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
9.37%
|
5.21%
|
13.2%
|
15.7%
|
17.2%
|
17.3%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
4.29%
|
9.94%
|
13.3%
|
14%
|
14.5%
|
Assets
1 |
-
|
-
|
4,231
|
5,041
|
5,342
|
6,652
|
7,721
|
Book Value Per Share
2 |
-
|
8.280
|
8.620
|
9.740
|
11.40
|
13.40
|
15.80
|
Cash Flow per Share
2 |
-
|
0.3600
|
0.1000
|
0.6200
|
1.060
|
1.800
|
2.230
|
Capex
1 |
-
|
633
|
291
|
471
|
290
|
163
|
180
|
Capex / Sales
|
-
|
52.65%
|
27.13%
|
25.79%
|
11.73%
|
5.38%
|
5.16%
|
Announcement Date
|
4/2/21
|
2/18/22
|
2/24/23
|
2/23/24
|
-
|
-
|
-
|
Last Close Price
29.85
CNY Average target price
54.56
CNY Spread / Average Target +82.80% Consensus |
1st Jan change
|
Capi.
|
---|
| -45.54% | 1.7B | | +5.31% | 72.01B | | +31.22% | 10.39B | | +41.28% | 5.26B | | -18.53% | 4.64B | | +18.24% | 3.7B | | +26.86% | 2.3B | | -39.52% | 1.8B | | -0.50% | 1.64B | | -0.73% | 1.58B |
Specialty & Advanced Pharmaceuticals
|